

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
VIRTUAL PLATFORM**

January 25, 2023

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/DrSwee first meeting of year announcement 2023.pdf](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/DrSwee%20first%20meeting%20of%20year%20announcement%202023.pdf)
- II. Roll Call
- III. Review of meeting transcript for October 19, 2022, meeting
[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/DURB meeting transcript 10-19-22.pdf](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/DURB%20meeting%20transcript%2010-19-22.pdf)
- IV. Review of draft meeting summary for October 19, 2022, meeting
- V. Secretary's report
- VI. Old Business
 - A. Ivermectin utilization report (YTD 12-19- 22)
 - B. CGRP utilization report 2021 versus 2022 (YTD 12-19-22)
 - C. Semaglutide utilization report January 2021 – September 2022, as of 12-19-22
 - D. Review of impact of Inflation Reduction Act on insulin cost
 - E. Summary of DURB suggested changes to proposed protocols (see links to protocols)
 - i. Glucagon-like peptide-1 receptor agonists for T2D
[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/GLP-1 agonists approved protocol 10-22.pdf](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/GLP-1%20agonists%20approved%20protocol%2010-22.pdf)
 - ii. Cholbam® (cholic acid)
[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/Cholbam Approved Protocol 10-22.pdf](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/Cholbam%20Approved%20Protocol%2010-22.pdf)
- VII. New Business
 - A. Proposed addendum to Spinraza®/Zolgensma® protocols
 - B. Proposed addendum to Imcivree® protocol
 - C. Proposed addendum to GLP-1 agonists protocol
 - D. Proposed addendum to Dupixent® protocol (atopic dermatitis)
 - E. Proposed protocol for Gattex® (teduglutide)
 - F. Proposed protocol for Hyftor® (sirolimus)
- VIII. A. Informational Highlights/Reports
 1. Gainwell Technologies/NJ HMO 3rd Quarter 2022 Prior Authorization Report
 2. Summary of DURB Action Items
 3. (a) DHS, DHSS and MCO Programs Top Drugs Report/Physicians Administered Drugs (by amount paid and by category)

FFS:

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/FFS_Top_Drugs_Report_November_2022.pdf

MCO:

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/MCO_Top_Drugs_Report_October_2022.pdf

FFS Category:

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/FFS_Top_Drugs_by_Category_November_2022.pdf

MCO Category:

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/MCO_Top_Drugs_by_Category_October_2022.pdf

(b) Antiviral drugs by amount paid

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2023/FFS_Antiviral_Drugs_November_2022.pdf

B. Medication information:

1. **Wisconsin Supreme Court to hear ivermectin treatment case**

<https://www.beckershospitalreview.com/hospital-physician-relationships/wisconsin-supreme-court-to-hear-ivermectin-treatment-case.html>

2. **FDA Announces Preliminary Assessment that Certain Naloxone Products Have the Potential to be Safe and Effective for Over-the-Counter Use**

[FDA Announces Preliminary Assessment that Certain Naloxone Products Have the Potential to be Safe and Effective for Over-the-Counter Use | FDA](#)

3. **The Tik Tok trend that triggered a diabetes drug shortage**

<https://www.mdedge.com/endocrinology/article/259863/obesity/tiktok-trend-triggered-diabetes-drug-shortage>

4. COVID-19 Vaccines information

<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>

IX. Updated Materials:

- a. Proposed protocol for Glucagon-like peptide-1 receptor agonists for T2D – approved October 2022
- b. Proposed protocol for Cholbam® (cholic acid) – approved October 2022